The demo achieved each its Principal endpoints, with semaglutide two.four mg demonstrating statistically significant and top-quality improvements in liver fibrosis without having worsening of steatohepatitis, together with resolution of steatohepatitis with no worsening of liver fibrosis in individuals with MASH when compared with placebo.1Semaglut